At the same time, he began making plans for a trial with Dr. J. C. Heuson of the European Breast Cancer Group, who was anxious to compare tamoxifen with Nafoxidine (an Upjohn compound which like tamoxifen could bind to the estrogen receptor, but unlike tamoxifen had several toxic side effects). The gene discussed is ESR1; the disease is breast carcinoma.